Related Experiment Video
Updated: Apr 19, 2026
09:52
Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
Published on: March 16, 2018
10.1K
Oxaliplatin and ototoxicity: is it really safe for hearing?
Salim Yüce1, Mehmet Metin Seker, Sema Koç
1Department of Ear, Nose, and Throat, Cumhuriyet University, Sivas, Turkey. salimyucekbb@hotmail.com
Turkish Journal of Medical Sciences
|January 2, 2015
Summary
This study found that oxaliplatin chemotherapy does not cause hearing loss. High-frequency audiometry and otoacoustic emission tests confirmed no ototoxic effects in patients receiving oxaliplatin treatment.
Area of Science:
- Oncology
- Ototoxicology
- Clinical Pharmacology
Background:
- Oxaliplatin is a key chemotherapy drug for solid tumors.
- Common side effects include neuropathy, GI toxicity, and neutropenia.
- Previous case reports suggested potential ototoxicity, but clinical trials were lacking.
Purpose of the Study:
- To investigate the ototoxic effects of oxaliplatin in cancer patients.
- To assess hearing function before and after oxaliplatin treatment.
Main Methods:
- 18 cancer patients (colorectal and pancreatic) were studied.
- Patients received either CapeOx or FOLFOX-6 regimens.
- High-frequency audiometry and otoacoustic emission tests evaluated hearing.
Main Results:
- No hearing loss was detected across all tested frequencies (500-16,000 Hz).
- Otoacoustic emission tests showed no significant pre- vs. post-treatment differences.
- Median treatment duration was 3.2 months.
Conclusions:
- Oxaliplatin demonstrates a reliable safety profile regarding ototoxicity.
- The findings support the continued use of oxaliplatin without significant hearing impairment concerns.
Related Concept Videos
01:31Hearing
59.1K
When we hear a sound, our nervous system is detecting sound waves—pressure waves of mechanical energy traveling through a medium. The frequency of the wave is perceived as pitch, while the amplitude is perceived as loudness.
59.1K
01:24Drug Toxicity: Risk factors
214
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
214
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
525
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
525
01:11Renal Failure: Dose Adjustments
629
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
629
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
4.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.3K